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toxoplasma encephalitis 
in an Allogeneic 
hematopoietic Stem Cell 
transplant recipient in 
Korea
To the Editor, 
Toxoplasma gondii is an intracellular protozoan para-
site. Immunocompetent persons with primary infection 
are usually asymptomatic, but latent infection can per-
sist for the life of the host [1]. In immunocompromised 
patients, however, a risk exists of reactivating the infec-
tion, which may become life-threatening [1].
Toxoplasmosis appears to be a rare opportunistic 
infection after hematopoietic stem cell transplantation 
(HSCT). The most frequently involved organ was the 
central nervous system (CNS), with 48% of patients 
having isolated cerebral infection and 76% of patients 
with disseminated disease showing brain involvement. 
Little is known about toxoplasmosis after HSCT in Ko-
rea. Here, we describe a Korean patient with isolated 
cerebral toxoplasmosis following allogeneic HSCT.
A 37-year-old woman was admitted because of head-
ache, myalgia, and fever. She had been well until 1 
week before admission, when her headache developed. 
Myalgia and fever occurred 5 days before admission 
and her headache worsened. Fifty days prior to admis-
sion, she had undergone HLA-matched sibling, non-T 
cell-depleted allogeneic HSCT for aplastic anemia. Her 
conditioning regimen included cyclophosphamide (50 
mg/kg a day for 4 consecutive days) and antithymo-
cyte immunoglobulin (3 mg/kg a day for 3 consecutive 
days), and prophylaxis against graft-versus-host disease 
(GVHD) consisted of short-course methotrexate (15 mg/
m
2 on day 1 and 10 mg/m
2 on days 3, 6, and 11) and cy-
closporine (4 mg/kg beginning 1 day before transplant).
The pre-transplant T. gondii serostatus of both donor 
and recipient was not known, but the recipient had 
been treated with clindamycin for toxoplasma uveitis 10 
years previously, at which time she was initially positive 
for toxoplasma IgM and negative for IgG, but became 
IgG-positive 5 months later.
Soon after HSCT (day 40, 2 weeks before admission), 
she developed grade II acute GVHD of the skin, and im-
munosuppressive therapy (i.e., methyl prednisone 48 
mg) was started. At the same time, gancyclovir (10 mg/
kg/day) therapy was initiated because she was cyto-
megalovirus (CMV) antigenemia-positive (41/200,000 
white blood cells). Fluconazole and acyclovir were 
administered as prophylaxis against candidiasis and 
herpes simplex infection, and pentamidine nebulizer 
was administered once monthly as prophylaxis against 
Pneumocystis jirovecii.
On admission (day 57), her blood pressure was 124/84 
mmHg, her pulse was palpable at 94 beats per minute, 
and her temperature was 38.8°C. At admission, she had 
a white blood cell count of 1,200/mm
3 with an absolute 
neutrophil count of 880/mm
3, a hemoglobin level of 9.2 
g/dL, a hematocrit of 30.6%, a platelet count of 59,000/
mm
3, and a C-reactive protein concentration of 4.29 
mg/dL. She took methyl prednisone 6 mg, which had 
been tapered from the initial dose of 48 mg, for treat-
ment of acute GVHD. Brain magnetic resonance imag-
ing (MRI) revealed focal high signal intensity (SI) in the 
right caudate nucleus and right thalamus on T2 weight-
ed images and combined subtle ring-enhancement of 
the lesions (Fig. 1A and 1B). Toxoplasma serology re-
vealed an equivocal IgG titer (7 IU/mL) and negative 
IgM titer on hospital day (HD) 1. She was negative for 
serum galactomanan. A lumbar puncture yielded clear 
cerebrospinal fluid (CSF) with a white blood count of 2/
mm
3, including 3% neutrophils and 63% lymphocytes, 
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a protein concentration of 24 mg/dL, and a glucose con-
centration of 72 mg/dL. Bacterial, fungal, and mycobac-
terial cultures of her CSF were negative. Microbiologic 
or molecular tests in CSF for viruses such as herpes 
simplex virus, human herpes virus-6, CMV, and Ep-
stein-Barr virus were not performed because multiple 
ring-enhancing lesions are unusual in viral encephalitis. 
Ophthalmic examination revealed only pseudophakia 
in the right eye and no evidence of inflammation. Bron-
choalveolar lavage was not performed because chest 
computed tomography (CT) showed no abnormal find-
ings in lung parenchyma and lymph nodes. Abdominal 
CT and electrocardiogram showed nonspecific findings, 
except underlying Woff-Parkinson-White syndrome. 
On HD 4, her serum was tested for T. gondii using an 
in-house specific polymerase chain reaction (PCR) as-
say [2]. She began empirical treatment with merope-
nem + vancomycin + itraconazole and pyrimethamine 
(200 mg loading then 75 mg daily) + sulfadiazine (6 g 
daily) for T. gondii. On HD 11, 6 days after initiation 
of anti-toxoplasma therapy, her headache had slightly 
improved, and MRI of her brain showed that the lesions 
Figure 1. Magnetic resonance imaging of the brain. Focal high signal intensity in the right caudate nucleus (A) and the right thalamus 
(B) on combined subtle ring-enhancement of the lesions was observed. Fifty days after initiation of anti-toxoplasma therapy, the lesions 
had nearly disappeared (C and D). 
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in the right caudate nucleus and right thalamus had 
decreased in size. On HD 15, serum PCR amplification 
of the sample taken on HD 4 showed T. gondii-specific 
bands (Fig. 2 and 3). We therefore discontinued other 
antibiotics and antifungal agents and continued anti-
toxoplasma therapy only. T. gondii-specific bands were 
not detected 10 days after initiation of anti-toxoplasma 
therapy.
Because MRI of the brain showed that the lesions 
had nearly disappeared 50 days after initiation of anti-
toxoplasma therapy (Fig. 1C and 1D) and her headache 
had mostly improved, she was discharged from the 
hospital and continued maintenance anti-toxoplasma 
therapy with pyrimethamine (50 mg daily) + sulfa-
diazine (3 g daily) for 2 months, and trimethoprim-
sulfamethoxazole (TMP-SMX) (5-25 mg/kg/day) for 10 
months. Twelve months later, all symptoms related to 
toxoplasmosis had disappeared.
HSCT has been associated with several neurologic 
complications secondary to the underlying disease and 
to prolonged myelosuppression. The most common 
neurologic complications are CNS infection, marked by 
early onset within the first 4 months after HSCT (87%), 
diagnostic difficulties, and a high mortality rate (47%). 
These infections consisted primarily of cerebral toxo-
plasmosis, fungal infections, and viral encephalitis [3]. 
Humans can acquire toxoplasmosis in four ways: 
ingestion of infectious oocytes from the environment 
(usually from soil contaminated with feline feces), in-
gestion of tissue cysts in meat from an infected animal, 
vertical transmission from an infected mother to her 
fetus, and blood transfusion or organ transplantation 
from an infected donor [1]. Our patient had anti-toxo-
plasma IgG antibody prior to HSCT, and she had grown 
up with many animals in her garden, including cats. 
Since the pre-transplant T. gondii serostatus of both 
donor and recipient was not known, whether in this 
case toxoplasmosis was due to reactivation of a latent 
infection or primary infection from an infected donor is 
unclear. 
Diagnosis of toxoplasmosis in transplant recipients 
is often difficult because of the nonspecific signs and 
symptoms of the infection. Sensitive and specific non-
invasive methods for detection of T. gondii are needed, 
since invasive procedures in HSCT recipients carry a 
high risk of complications. In our patient, stereotactic 
brain biopsy was attempted for histological assessment, 
but failed because the lesions were located in vital re-
gions of the brain or inaccessible to biopsy, as well as 
being small enough to render biopsy infeasible.
PCR techniques have been developed for noninvasive 
diagnosis of cerebral toxoplasmosis in patients with ac-
Figure 2. Polymerase chain reaction analysis for detection 
of Toxoplasma gondii. M, DNA marker; A, positive control; B, 
patient; C, negative control.
Figure 3. Flowchart of the patient’s clinical progress. Fever 
and C-reactive protein (CRP) decreased after initiation of anti-
toxoplasma therapy, antibiotics, and antifungal agents. Only 
anti-toxoplasma therapy was continued after confirmation by 
Toxoplasma gondii-specific polymerase chain reaction (PCR). T. 
gondii-specific bands were not detected 10 days after initiation of 
anti-toxoplasma therapy.
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quired immune deficiency syndrome (AIDS), and have 
contributed to the rapid diagnosis and monitoring of 
treatment efficacy and may improve patient outcomes 
[4]. PCR analysis of the serum of our patient showed 
initial positivity for T. gondii, with negativity observed 
10 days after initiation of anti-toxoplasma therapy. Ac-
cording to the proposed definitions for toxoplasmosis 
after HSCT [5], the diagnosis in our patient was prob-
able toxoplasma disease, defined as clinical and radio-
logic evidence suggestive of organ involvement plus at 
least one positive PCR test from blood, CSF, or bron-
choalveolar lavage, but no histology confirmation, and 
absence of another pathogen that may explain findings. 
Although histological confirmation failed in this case, 
tissue biopsy for histological assessment is necessary 
for confirmation in patients with suspected cerebral 
toxoplasmosis.
Another noninvasive diagnostic method is MRI. Most 
neuroradiological studies on toxoplasma have been 
performed in patients with AIDS, with typical findings 
including multiple, ring-enhancing brain lesions often 
associated with edema. However, CNS lymphoma and 
other infections, including cryptococcus, aspergillosis, 
and tuberculosis, should be differentiated as they cause 
similar lesions [2].
Prophylaxis prior to HSCT should be considered for 
all recipients who are seropositive for toxoplasma and 
have risk factors for reactivation (e.g., GVHD). TMP-
SMX or pyrimethamine/sulfadoxine prophylaxis may 
be effective in preventing T. gondii and P. jirovecii in-
fection. In two patients from Korea, including this one 
and another with bilateral toxoplasma choroidoretinits 
after allogeneic HSCT, a monthly pentamidine inhala-
tion was prophylactic against P. jirovecii after HSCT, 
but this agent has no effect on T. gondii. Given that our 
patient had previous toxoplasma uveitis with positive 
anti-toxoplasma IgG antibody 10 years prior to HSCT, 
such a prophylactic regimen was inappropriate. After 
our experience with these two patients with cerebral 
toxoplasmosis after allogeneic HSCT, the prophylaxis 
regimen in our hospital changed from a pentamidine 
nebulizer to TMP-SMX. 
In summary, we describe here a Korean patient with 
cerebral toxoplasmosis following HSCT. This patient 
was diagnosed with probable cerebral toxoplasma dis-
ease by clinical and radiologic evidence suggestive of 
brain involvement and a positive blood PCR test.
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